IV Nutrient Therapy in Radiation Recovery

Presented at:
IV Therapy 2013 Conference and Expo
Integrative Oncology and Chronic Illness
by
Virginia Osborne, ND and Paul Anderson, ND

Copyright IVNTP
Radiation Injury Therapy
Support for Nerve Function and Repair
Neuro-regeneration

- Neurological cells (and all others) are incredibly sensitive to mitochondrial damage, cell membrane damage and other effects.

- Many oncologic therapies have deleterious effects on the cell matrix and nerve function, leading to significant decreases in quality of life.

- Supplementation and augmentation of glutathione function can aid in the regeneration of all damaged neurological tissues.
Glutathione

• Proven beneficial in pre loading doses prior to radiation.
• Studies showing further benefit post radiation treatments
• Decreases post treatment neuropathy
• Supports p53 activity through the redox modulation enhancing tumor apoptosis.
Glutathione

- Glutathione (GSH) and the augmentation of its function appear in early trials at the Bastyr Integrative Oncology Research Center to aid greatly in repair of radiation and chemotherapy induced neuropathies.
- Data are preliminary, but if general pharmacokinetic and dynamic parameters are observed GSH can be safely used in the patient with cancer.
Glutathione and Cofactors

H₂O₂

2 GSH (Red)

Glut. Peroxidase [Se]

GSSG (Ox)

NADP+

[B₂-FAD] Glut. Reductase

[B₃-NADPH+H]

HMP Shunt

Magnesium & B-5

2 H₂O
Glutathione and B-5

- Slyshenkov VS, Dymkowska D, Wojtczak L. Pantothenic acid and pantothenol increase biosynthesis of glutathione by boosting cell energetics. FEBS Lett. 2004 Jul 2;569(1-3):169-72. Source Nencki Institute of Experimental Biology, Pasteura 3, 02-093 Warsaw, Poland. PMID: 15225628

- Wojtczak L, Slyshenkov VS. Protection by pantothenic acid against apoptosis and cell damage by oxygen free radicals--the role of glutathione. Source Nencki Institute of Experimental Biology, Pasteura 3, 02-093 Warsaw, Poland. LWAC@nencki.gov.pl PMID: 12897429
Glutathione and RBC Mg

Abstract—Recent evidence suggests that the endogenous antioxidant glutathione may play a protective role in cardiovascular disease. To directly investigate the role of glutathione in the regulation of glucose metabolism in hypertension, we studied the acute effects of in vivo infusions of this antioxidant (alone or in combination with insulin) on whole body glucose disposal (WBGD) using euglycemic glucose clamp and the effects on total red blood cell intracellular magnesium (RBC-Mg) in hypertensive (n=520) and normotensive (n=530) subjects. The relationships among WBGD, circulating reduced/oxidized glutathione (GSH/GSSG) levels, and RBC-Mg in both groups were evaluated. The in vitro effects of glutathione (100 mmol/L) on RBC free cytosolic magnesium (Mgi) were also studied. In vivo infusions of glutathione (15 mg/min×120 minutes) increased RBC-Mg in both normotensives and hypertensives (1.99±0.02 to 2.13±0.03 mmol/L, P<0.01, and 1.69±0.03 to 1.81±0.03 mmol/L, P<0.01, respectively). In vitro GSH but not GSSG increased Mgi (179±6 to 214±5 mmol/L, P<0.01). In basal conditions, RBC-Mg values were related to GSH/GSSG ratios (r=0.84, P<0.0001), and WBGD was directly, significantly, and independently related to both GSH/GSSG ratios (r=0.79, P<0.0001) and RBC-Mg (r=0.89, P<0.0001). This was also true when hypertensive and control groups were analyzed separately. On multivariate analysis, basal RBC-Mg (t=56.81, P<0.001), GSH/GSSG (t=53.67, P<0.02), and blood pressure (t=52.89, P<0.05) were each independent determinants of WBGD, with RBC-Mg explaining 31% of the variability of WBGD. These data demonstrate a direct action of glutathione both in vivo and in vitro to enhance intracellular magnesium and a clinical linkage between cellular magnesium, GSH/GSSG ratios, and tissue glucose metabolism.

Glutathione and Oxidative Stress

Abstract

To evaluate the relationship between oxidative stress and glucose metabolism, insulin sensitivity and intraerythrocytic reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio were measured in 10 non-insulin-dependent diabetes mellitus (NIDDM) patients and 10 healthy subjects before and after the intravenous administration of GSH. In particular, after baseline insulin sensitivity was assessed by a 2-hour euglycemic hyperinsulinemic clamp, either glutathione (1.35 g x m2 x min(-1)) or placebo (saline) were infused over a period of 1 hour.

In conclusion, our data support the hypothesis that abnormal intracellular GSH redox status plays an important role in reducing insulin sensitivity in NIDDM patients. Accordingly, intravenous GSH infusion significantly increased both intraerythrocytic GSH/GSSG ratio and total glucose uptake in the same patients.

Does GSH decrease after cancer treatment?

Conclusions: A significant decline in GSH–glutathione disulfide, cysteine-cystine, and vitamin E status occurs after chemotherapy and BMT. Standard PN does not improve antioxidant status compared with administration of micronutrients alone. Further evaluation of PN formulations to support patients undergoing high-dose chemotherapy and BMT are needed.

Purpose: We performed a randomized, doubleblind, placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of oxaliplatin-induced neurotoxicity.

Patients and Methods: Fifty-two patients treated with a bimonthly oxaliplatin-based regimen were randomized to receive GSH (1,500 mg/m2 over a 15-minute infusion period before oxaliplatin) or normal saline solution. Clinical neurologic evaluation and electrophysiologic investigations were performed at baseline and after four (oxaliplatin dose, 400 mg/m2), eight (oxaliplatin dose, 800 mg/m2), and 12 (oxaliplatin dose, 1,200 mg/m2) cycles of treatment.

Conclusion: This study provides evidence that GSH is a promising drug for the prevention of oxaliplatin-induced neuropathy, and that it does not reduce the clinical activity of oxaliplatin.

GSH and Oxaliplatin

Abstract

Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer. However, the oxaliplatin-induced neurotoxicity still represents a clinical problem leading to a discontinuation of the therapy. Many strategies have been proposed in order to manage the neurotoxicity, but their effect on antitumoral efficacy is still unclear. In this study, we investigated the effect of reduced glutathione administration on neurotoxicity, oxaliplatin pharmacokinetics, and platinum-DNA (Pt-DNA) adduct formation in patients affected by colorectal cancer treated with FOLFOX4 adjuvant regimen.

GSH and Oxaliplatin

Abstract

In conclusion, this study indicates that coadministration of GSH is an effective strategy to reduce the oxaliplatin-induced neurotoxicity without impairing neither the pharmacokinetics of oxaliplatin, nor the Pt-DNA adduct formation.

Abstract

Using a human fibroblast strain deficient in glutathione synthetase and a related proficient control strain, the role of glutathione (GSH) in repair of potentially lethal damage (PLD) has been investigated in determining survival by plating cells immediately or 24 h after irradiation. After oxic or hypoxic irradiation, both cell strains repair radiation-induced damage. However, under hypoxic conditions, the proficient cells repair PLD as well as under oxic conditions while the deficient cells repair less PLD after irradiation under hypoxic than under oxic conditions...

The results indicate that GSH is involved in PLD repair and, in particular, in the repair of damage induced by radiation delivered under hypoxic conditions.

Abstract
Endogenous thiols, especially the tripeptide-reduced glutathione (GSH), are known to play an important role in cellular defense against radiation. However, there are evidences that suggest that GSH may not be an efficient protector of DNA. The present study will determine whether modulation of endogenous GSH levels protects or potentiates the amount of chromosomal damage induced by ionizing radiation (IR). Human lymphocytes were isolated and then treated with GSH (for 1h) or buthionine sulfoximine (BSO; GSH-depleting agent for 5 h) before X-irradiation. DNA damage was analyzed by scoring chromosome aberrations (CAs) and by comet assay. The level of endogenous GSH was measured in lymphocytes treated with GSH, BSO or X-rays. A roughly 20% increase in endogenous GSH level was observed after a 3-h treatment with exogenous GSH and this reduced the frequency of all types of CA and aberrant metaphase chromosomes induced by 1 and 2 Gy of X-rays and also decreased the tail moment as determined by comet assay, suggesting radiation protection. Such uniform protection by GSH pretreatment was not visible while cells were exposed to 3 Gy or higher. Interestingly, in GSH-depleted lymphocytes, the frequency of radiation-induced CA was increased in a non-uniform manner.

Abstract

Therefore, an increase in the level of endogenous GSH in lymphocytes was unable to reduce chromosomal damage induced by 3 Gy or above, whereas decrease in the level of GSH enhanced the frequency of CA at all radiation doses in a non-uniform manner. It seems that GSH did not act as a radioprotector against DNA damage induced by higher dose X-rays rather it acts as a modulator of DNA repair activity.

Glutathione and HDIVC on the same day:

Two popular complementary, alternative, and integrative medicine therapies, high-dose intravenous ascorbic acid (AA) and intravenous glutathione (GSH), are often coadministered to cancer patients with unclear efficacy and drug-drug interaction. Treatment in mouse pancreatic cancer xenografts showed that intraperitoneal AA at 4g/kg daily reduced tumor volume by 42%. Addition of intraperitoneal GSH inhibited the AA-induced tumor volume reduction.

There is an antagonism between ascorbate and glutathione in treating cancer, and therefore iv AA and iv GSH should not be coadministered to cancer patients on the same day.

• Due to High dose Vit C as an oxidant
• Glutathione promotes the anti-oxidant cycles